Sucampo Pharma (SCMP) Tops Q2 EPS by 6c; Boosts FY15 EPS Outlook

Sucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.21, $0.06 better than the analyst estimate of $0.15. Revenue for the quarter came in at $34.9 million versus the consensus estimate of $31.9 million.

Sucampo Pharma sees FY2015 EPS of $0.65-$0.75, versus the consensus of $0.62.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance